Guardant Health Inc’s filing revealed that its Director Tariq Musa unloaded Company’s shares for reported $11769.0 on Dec 17 ’25. In the deal valued at $101.46 per share,116 shares were sold. As a result of this transaction, Tariq Musa now holds 7,993 shares worth roughly $0.81 million.
Then, Eltoukhy Helmy sold 90,565 shares, generating $9,402,220 in total proceeds. Upon selling the shares at $103.82, the Co-Chief Executive Officer now owns 2,047,143 shares.
Before that, Chudova Darya sold 5,451 shares. Guardant Health Inc shares valued at $567,132 were divested by the Chief Technology Officer at a price of $104.04 per share. As a result of the transaction, Chudova Darya now holds 7,012 shares, worth roughly $0.71 million.
A number of analysts have revised their coverage, including Wolfe Research’s analysts, who increased its forecast for the stock in late September from “a Peer perform” to “an Outperform”. Mizuho started covering the stock on April 10, 2025. It rated GH as “an Outperform”.
Price Performance Review of GH
On Monday, Guardant Health Inc [NASDAQ:GH] saw its stock jump 1.60% to $101.34. Over the last five days, the stock has lost -1.30%. Guardant Health Inc shares have risen nearly 213.16% since the year began. Nevertheless, the stocks have risen 231.72% over the past one year. While a 52-week high of $112.43 was reached on 11/25/25, a 52-week low of $29.91 was recorded on 01/02/25.
Levels Of Support And Resistance For GH Stock
The 24-hour chart illustrates a support level at 100.03, which if violated will result in even more drops to 98.71. On the upside, there is a resistance level at 102.40. A further resistance level may holdings at 103.46.
How much short interest is there in Guardant Health Inc?
A steep rise in short interest was recorded in Guardant Health Inc stocks on 2025-11-28, growing by 0.83 million shares to a total of 9.25 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 8.42 million shares. There was a rise of 8.98%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 23, 2025 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $60 price target.
